Article (Published version) (998 Kb) - 
Limited access to UNIGEOther version: https://www.sciencedirect.com/science/article/pii/S1474442219301528
Highlights
Scientific Article - Review
unige:123501 
 |
Recent developments in drug-induced movement disorders: a mixed picture |
|
| Authors | ||
| Published in | The Lancet neurology. 2019, vol. 18, no. 9, p. 880-890 | |
| Abstract | A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism. | |
| Identifiers | PMID: 31279747 | |
| Full text |
Article (Published version) (998 Kb) - Limited access to UNIGE Other version: https://www.sciencedirect.com/science/article/pii/S1474442219301528 |
|
| Structures | ||
| Research group | Groupe Pierre Burkhard (neurologie) (154) | |
| Citation (ISO format) | FACTOR, Stewart A et al. Recent developments in drug-induced movement disorders: a mixed picture. In: The Lancet Neurology, 2019, vol. 18, n° 9, p. 880-890. doi: 10.1016/S1474-4422(19)30152-8 https://archive-ouverte.unige.ch/unige:123501 |
246 hits 
1 download 
Contact an author
Update